FDA Approves New Hepatitis B Treatment
Treatment of Hepatitis B from FDA Hepatitis B is a viral infection that primarily attacks the liver and can cause both acute and chronic diseases. It is a major global health problem and estimated to affect over 240 million people worldwide. In the United States, the Food and Drug Administration (FDA) plays a crucial role in evaluating and approving treatments for hepatitis B. With advancements in medical research and technology, several effective treatments have emerged over the years, greatly improving the prognosis for patients with this condition. The FDA has approved various antiviral medications for the treatment of hepatitis B. These medications act by inhibiting the replication of the virus, thus preventing further damage to the liver. Currently, there are seven FDA-approved antiviral drugs for the management of chronic hepatitis B: interferon alfa-2b, pegylated interferon alfa-2a, lamivudine, adefovir dipivoxil, entecavir, telbivudine, and tenofovir disoproxil fumarate. Interf